Over the past six months, Octavian has sharpened its focus on small molecule drug discovery targeting the endocannabinoid system. Its lead candidate, a patent-protected small molecule new chemical ...

Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as Octavian Therapeutics to align with its “growth ambitions and its ...

And after playing through the demo area with a poison build Ranger ... of Exile 2 is scheduled to release in early 2025. The post Octavian Shares Why Adding WASD Controls to Path of Exile 2 ...